摘要
目的:探究乙型肝炎肝硬化患者采取恩替卡韦联合胸腺肽治疗的临床疗效,并为该病的临床治疗积累经验。方法:选取我院于2010年4月至2013年2月收治的68例乙型肝炎肝硬化患者,利用随机数字表法进行分组,分别设为研究组和对照组,每组各34例。两组均给予常规对症治疗,其中研究组给予恩替卡韦联合胸腺肽治疗,对照组仅给予恩替卡韦治疗。记录两组治疗前后肝功能及肝纤维化四项情况,并做好对比。结果:两组在治疗前肝功能及肝纤维化四项数值差异无统计学意义(P>0.05);治疗后,研究组TB和ALT值低于对照组(P<0.05),ALB值高于对照组(P<0.05);研究组肝纤维化四项数值均低于对照组,差异有统计学意义(P<0.05)。结论:恩替卡韦联合胸腺肽在改善乙型肝炎肝硬化患者肝功能及肝纤维化方面的效果较佳,且抗病毒能力较强,取得较为满意的临床疗效。
Objective： To investigate the clinical effect of entecavir plus thymosin for patients with hepatitis B cirrhosis,and provide experience for the clinical treatment of the disease. Method： A total of 68 patients with hepatitis B cirrhosis from April 2010 to February 2013 in our hospital,were divided into the observation group and the control group randomly,34 patients in each group. The observation group were given the treatment of entecavir plus thymosin and the control group were given the treatment of entecavir on the basis of conventional symptomatic treatment. Before and after treatment,the liver function and four indexes of hepatic fibrosis of two groups were recorded and compared. Result： Before treatment,the liver function and four indexes of hepatic fibrosis of two groups had no statistical significance（ P ＆gt;0.05）.After treatment,the TB and ALT of the observation group were lower than the control group（ P ＆lt; 0.05）,and the ALB value was higher than the control group（ P ＆lt; 0.05）. Four indexes of hepatic fibrosis of the observation group was lower than the control group,and the difference had statistical significance（ P ＆lt; 0.05）. Conclusion： The clinical effect of entecavir plus thymosin on improving the liver function of patients with hepatitis B cirrhosis is effective,has the strong antiviral ability,and achieve satisfactory clinical efficacy.
出处
《河北医学》
CAS
2014年第2期239-242,共4页
Hebei Medicine
